PAX5 and non-small cell lung carcinoma: To confirm whether the promoter methylation resulted in the silence of PAX5 in NSCLC, three cell lines, A549, H1395 and H1975, which have silenced or reduced PAX5 expression, were treated with the DNA methyltransferase inhibitors (5‐aza‐2‐deoxycytidine, 5‐Aza) combined with the histone deacetylase inhibitor (TSA).